“Teriparatide pre-filled injection pen is a synthetic follow-on version for the recombinant (biological) teriparatide (Forsteo®) indicated for treatment of osteoporosis and it has been developed by utilizing fast-developing synthetic technologies. The addition of this non-biological complex drug is a terrific supplement to the existing portfolio and our strategic focus on specialty medicine. In addition, we have secured a new strategic partnership which can be an advantage when sourcing future products.” says Mr Lars Minor CEO of Newbury

Regulatory filling will take place during the next years, and we aim to launch this medicine in Sweden and Denmark where the total annual value of the market is estimated to be 4,6 MEUR according to DLMI Nordic Pharma Insights.
 
Newbury currently has thirty (30) products in its portfolio and first launches are taking place in 2022 with additional launches planned in the years ahead. The expected launch date of Teriparatide Newbury will be announced closer to the expected launch in 2024.

”Newbury is a company with high ambitions and we are rapidly growing our portfolio. We want to be known as the local champion and alternative partner of choice and we strive to have a positive impact in society” says Mr Karl Karlsson Founder & Chairman. 

Teriparatide injection is used to treat osteoporosis (a condition in which the bones become thin and weak and break easily) in men and in women who have undergone menopause, who are at high risk of fractures (broken bones). Teriparatide injection is also used to treat osteoporosis in men and women who are taking corticosteroids who are at high risk of fractures, and cannot use other osteoporosis treatments. Teriparatide injection contains a synthetic form of natural human hormone called parathyroid hormone (PTH). It works by causing the body to build new bone and by increasing bone strength and density (thickness).